Australia recently launched a countrywide immunotherapy program for infants with peanut allergies. The program is a partnership between the Murdoch Children’s Research Institute and the country’s National Allergy Center of Excellence. This is the first time a countrywide program for peanut allergies is being integrated into mainstream care globally.
The program, whose objective is to safely build tolerance and hopefully achieve remission, is available for babies under 12 months who have been diagnosed with peanut allergies. The infants must be under the care of an allergy specialist in one of the 10 public pediatric hospitals across the states taking part in the program.
The treatment will be free to eligible patients and will involve the scheduled and daily administration of a calculated dose of peanut powder at the patient’s home during a two-year period. The aim is to regulate the children’s immune system while it’s still malleable. Evidence has shown that younger children respond well to this oral immunotherapy approach, both by a decreased risk of reactions and better effectiveness.
Professor Kirsten Perrett, population allergy lead at the Murdoch Children’s Research Institute, stated that the institute’s focus was changing the trajectory of allergic illnesses in the country so that more children could go to school without the risk of a life-threatening reaction to peanuts. Perrett, who is also director of the National Allergy Center of Excellence, expects demand to be high, particularly since Australia is the world’s allergy capital.
Currently, five million individuals in the country suffer from allergic illnesses, with roughly 3% of 12-month-old infants also being affected by peanut allergies.
The program is being funded by the federal government of Australia. Its results will be assessed by the National Allergy Center of Excellence, with the intention of launching it to more allergy clinics and hospitals if successful. Eventually, Perrett noted, the program could even be extended to older children.
Professor Adam Fox, a specialist in pediatric allergy, praised the move, stating in an interview that this was an exciting initiative, and he would await the outcome. Fox, who is also the chair of the National Allergy Strategy Group in the United Kingdom, added that using early aggressive interventions grew the chance of reversing high rates of peanut allergies in Australia.
Food allergies are also a problem in the United States, with estimates showing that roughly 2% of kids are affected by peanut allergies. Peanuts are said to cause severe allergic reactions, including a life-threatening reaction called anaphylaxis.
The field of immunotherapy also has numerous for-profit enterprises, such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), that are focused on developing therapies for the treatment of various forms of cancer as well as infectious diseases. The success of these efforts could bring much-needed relief to l patients around the world.
NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused…
Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The…
Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio…
The FIFA World Cup started on June 11 and will end on July 19. 48…
A study conducted by a team at Mass General Brigham has found that people with…